Three Hoosier Cancer Research Network (HCRN) investigator-initiator clinical trials will be highlighted during the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, CA.

HCRN will hosting in-person meetings for the Gastrointestinal Clinical Trial Working Group on Friday, January 20, 2023 at the San Francisco Marriot Marquis at 7 pm PT.

Request call in information to join remotely.  

HCRN GI19-405

Session Title: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.

Abstract Number: TPS629 Poster Number: N18

A Phase II Study of Atezolizumab (ATEZO) and Bevacizumab (Bev) in Combination with Y90 TARE in Patients (Pts) with Hepatocellular Carcinoma (HCC).

Presented By: Renuka V. Iyer of Roswell Park Cancer Institute, Buffalo, NY

Authors: Renuka V. Iyer, Michael Petroziello, Nainesh Parikh, Richard D. Kim, Thatcher Ross Heumann, Daniel Brown, Kevin Kim, Yixing Jiang, Suvranu Ganguli, Eric Marks, Beau Toskich, Umair Majeed, Shamar Young, Rachna T. Shroff, Moh’d M. Khushman, Andrew Gunn, Filip Banovac, Aiwu Ruth He

Organizations

Roswell Park Cancer Institute, Roswell park Comprehensive Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Vanderbilt University, University of Maryland, Boston Medical Center, Boston University School of Medicine, Mayo Clinic Division of Vascular/Interventional Radiology, Mayo Clinic Florida, University of Minnesota, University of Arizona Cancer Center, University of Alabama School of Medicine, The University of Alabama at Birmingham, Georgetown University Medical Center.

HCRN GI16-288

Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus

Abstract Number: 103 Poster Number: E20

A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for respectable hepatic-limited metastatic colorectal cancer: preliminary efficacy and correlative results.

Presented by: Kristen Renee Spencer of Perlmutter Cancer Center of NYU Langone Health/NYU Grossman School of Medicine, New York, NY;

Kristen Renee Spencer, Howard S. Hochster, Patrick M Boland, Lyudmyla Derby Berim, Timothy Kennedy, Miral Grandhi, Russell C Langan, Dirk F. Moore, Michael P. Kane, Smitha S. Krishnamurthi, Skye C. Mayo, Anup Kasi, Agustin Pimentel, Darren R. Carpizo

Organizations

Perlmutter Cancer Center of NYU Langone Health/NYU Grossman School of Medicine, Rutgers Cancer Institute of New Jersey, Cleveland Clinic, Cleveland, OHSU Knight Cancer Institute, University of Kansas Medical Center, University of Miami, University of Rochester.

HCRN GI15-225

Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Abstract Number: 534 Poster Number: C4

A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC).

Presented by: Ashwin Somasundaram of the University of North Carolina at Chapel Hill.

Authors: Ashwin Somasundaram, Paul R. Helft, William Proctor Harris, Hanna Kelly Sanoff, Guy E. Johnson, Menggang Yu, Matthew Johnson, Bert O’Neil, Autumn Jackson McRee

Organizations

The University of North Carolina at Chapel Hill, Indiana University Simon Cancer Center, University of Washington/FHCC, University of North Carolina, University of Washington, University of Wisconsin, Indiana University Department of Radiology and Imaging, Community Health Network, Janssen Research & Development.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.